Santhera Pharmaceuticals (SPHDF) News Today → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free SPHDF Stock Alerts $11.70 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSanthera : Vamorolone NDA Accepted For Priority Review By China' NMPA In Duchenne Muscular Dystrophymarkets.businessinsider.com - March 27 at 8:47 AMSanthera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPAfinance.yahoo.com - March 27 at 8:47 AMSanthera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurologyfinance.yahoo.com - February 14 at 3:50 AMSanthera Pharmaceuticals Holding AG 0QN1morningstar.com - February 3 at 2:55 PMSanthera Pharmaceuticals Holding AG (SANN.SW)finance.yahoo.com - January 31 at 4:29 AMSanthera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophyfinance.yahoo.com - January 15 at 9:25 AMAnalysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Ironwood Pharma (IRWD) and Cytokinetics (CYTK)markets.businessinsider.com - January 12 at 2:25 PMSanthera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdomfinance.yahoo.com - January 12 at 9:24 AMSanthera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophyfinance.yahoo.com - December 18 at 8:32 AMSanthera Appoints Executive Committee Members as it Transitions into Commercial Stagefinance.yahoo.com - December 7 at 8:30 AMSanthera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophyfinance.yahoo.com - October 27 at 10:07 AMUS FDA approves Santhera's Duschenne drugreuters.com - October 26 at 6:06 PMSanthera: Europe's CHMP Issues Positive Opinion For AGAMREE To Treat Duchenne Muscular Dystrophymarkets.businessinsider.com - October 13 at 10:42 AMPositive European Approval Outlook for Santhera’s AGAMREE Bolsters Buy Rating: Potential Milestone for DMD Treatmentmarkets.businessinsider.com - October 13 at 10:42 AMSanthera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophyfinance.yahoo.com - October 13 at 10:42 AMSanthera Pharmaceuticals reports 1H resultsseekingalpha.com - September 8 at 5:50 AMSanthera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The Cornerfinance.yahoo.com - September 8 at 5:50 AMSanthera Announces Half-Year 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - September 7 at 2:52 AMSanthera Completes Divestment of Raxone®/Idebenone Business to Chiesi Groupbenzinga.com - July 31 at 10:30 AMH.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)markets.businessinsider.com - July 31 at 10:30 AMSanthera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share Splitfinanznachrichten.de - June 29 at 1:27 AMSanthera Publishes Timeline of the Reverse Share Splitfinance.yahoo.com - June 29 at 1:27 AMSanthera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General Meetingfinanznachrichten.de - June 27 at 12:51 PMShareholders Approve all Board Proposals at Today’s Annual General Meetingfinance.yahoo.com - June 27 at 12:51 PMCatalyst (CPRX) to Gain DMD Drug Licensing Rights From Santheramsn.com - June 21 at 9:55 AMCatalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticalsfinance.yahoo.com - June 20 at 7:03 AMSanthera Grants North America License For Vamorolone To Catalyst Pharmamarkets.businessinsider.com - June 20 at 1:46 AMSanthera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royaltiesfinance.yahoo.com - June 20 at 1:46 AMSanthera Publishes Agenda for its Annual General Meetingfinance.yahoo.com - June 6 at 4:19 AMSanthera Pharmaceuticals GAAP EPS of -CHF1.17seekingalpha.com - June 2 at 10:21 AMSanthera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022finanznachrichten.de - June 1 at 10:18 AMSanthera Publishes Annual Report 2022finance.yahoo.com - May 31 at 7:41 PMSanthera -- A Duchenne Drug With Positive Study Results That Few Know Aboutthestreet.com - May 24 at 8:06 AMSanthera Drug Wins European Approval for Rare Blindness Diseasethestreet.com - May 13 at 12:18 AMSanthera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Updatefinance.yahoo.com - April 27 at 9:35 AMSanthera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completedfinanznachrichten.de - April 25 at 9:42 AMVamorolone NDA mid-cycle review meeting by FDA completedfinance.yahoo.com - April 25 at 9:42 AMSanthera Pharmaceuticals Holding AG (VTX:SANN) Is Expected To Breakeven In The Near Futurefinance.yahoo.com - April 1 at 2:39 AMSanthera Pharmaceuticals Holding AGbarrons.com - March 30 at 2:11 PMSanthera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - March 2 at 1:49 AMSanthera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolonefinance.yahoo.com - February 8 at 1:27 AMSanthera Pharmaceuticals Holding AG: Santhera enters into CHF 5 million share exchange agreementfinanznachrichten.de - January 10 at 8:39 AMSanthera enters into CHF 5 million share exchange agreementfinance.yahoo.com - January 10 at 8:39 AMSanthera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - January 9 at 9:05 AMSanthera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meetingtechnews.tmcnet.com - November 29 at 8:31 PMSanthera Calls Extraordinary General Meeting to Seek Approval for Further Financingsfinance.yahoo.com - November 4 at 10:49 AMSanthera Announces Half-Year 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - October 31 at 2:16 AMEuropean Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - October 31 at 2:16 AMSanthera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophyfinance.yahoo.com - October 27 at 5:31 AMSanthera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congressfinance.yahoo.com - October 10 at 3:14 AM Get Santhera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 SPHDF Media Mentions By Week SPHDF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPHDF News Sentiment▼0.000.32▲Average Medical News Sentiment SPHDF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPHDF Articles This Week▼00▲SPHDF Articles Average Week Get Santhera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPHDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AGNPF News AKBLF News DRTSW News ARNI News ARTLW News ASCLF News AWKNF News AXIM News BRRGF News BCTXW News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SPHDF) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santhera Pharmaceuticals Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
